Xbiotech Stock Performance
| XBIT Stock | USD 3.42 0.10 2.84% |
The firm maintains a market beta of 1.48, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, XBiotech will likely underperform. At this point, XBiotech has a negative expected return of -0.86%. Please make sure to check out XBiotech's information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if XBiotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days XBiotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (2.84) | Five Day Return 5.23 | Year To Date Return (17.99) | Ten Year Return (85.29) | All Time Return (85.29) |
Dividend Date 2021-07-23 | Ex Dividend Date 2021-07-15 |
1 | Proactive Strategies - Stock Traders Daily | 12/19/2024 |
2 | XBiotech suspend son programme de rhumatologie | 12/24/2024 |
3 | XBiotech Appoints Renowned Scientist to Board of Directors - TipRanks | 12/31/2024 |
4 | Wolf Haldenstein Adler Freeman Herz LLP announces that it is investigating XBiotech for ... | 01/14/2025 |
5 | Acquisition by Mckenzie W Thorpe of 25000 shares of XBiotech at 16.21 subject to Rule 16b-3 | 01/17/2025 |
6 | Acquisition by Mckenzie W Thorpe of 37500 shares of XBiotech at 5.12 subject to Rule 16b-3 | 01/22/2025 |
7 | XBiotech stock hits 52-week low at 3.5 amid market challenges - Investing.com | 01/28/2025 |
8 | Disposition of 2470355 shares by John Simard of XBiotech at 4.048 subject to Rule 16b-3 | 01/31/2025 |
9 | Disposition of 10714 shares by John Simard of XBiotech at 12.5312 subject to Rule 16b-3 | 02/10/2025 |
10 | XBiotech stock plunges to 52-week low, touches 3.03 - Investing.com | 02/18/2025 |
11 | Disposition of 13484 shares by John Simard of XBiotech at 4.24 subject to Rule 16b-3 | 02/27/2025 |
12 | Acquisition by Libby Peter of 25000 shares of XBiotech at 18.25 subject to Rule 16b-3 | 02/28/2025 |
13 | Disposition of 19332 shares by Sushma Shivaswamy of XBiotech at 7.5 subject to Rule 16b-3 | 03/13/2025 |
| Begin Period Cash Flow | 157.3 M |
XBiotech |
XBiotech Relative Risk vs. Return Landscape
If you would invest 634.00 in XBiotech on December 19, 2024 and sell it today you would lose (292.00) from holding XBiotech or give up 46.06% of portfolio value over 90 days. XBiotech is currently does not generate positive expected returns and assumes 5.7311% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than XBiotech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
XBiotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for XBiotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as XBiotech, and traders can use it to determine the average amount a XBiotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1505
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XBIT |
Estimated Market Risk
| 5.73 actual daily | 51 51% of assets are less volatile |
Expected Return
| -0.86 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average XBiotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of XBiotech by adding XBiotech to a well-diversified portfolio.
XBiotech Fundamentals Growth
XBiotech Stock prices reflect investors' perceptions of the future prospects and financial health of XBiotech, and XBiotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XBiotech Stock performance.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.12 | ||||
| Current Valuation | (65.82 M) | ||||
| Shares Outstanding | 30.48 M | ||||
| Price To Earning | 1.21 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 12.23 X | ||||
| Revenue | 300 K | ||||
| Gross Profit | 3.36 M | ||||
| EBITDA | (35.77 M) | ||||
| Net Income | (24.56 M) | ||||
| Cash And Equivalents | 225.79 M | ||||
| Cash Per Share | 7.42 X | ||||
| Total Debt | 7.77 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 28.99 X | ||||
| Book Value Per Share | 6.30 X | ||||
| Cash Flow From Operations | (18.73 M) | ||||
| Earnings Per Share | (1.08) X | ||||
| Market Capitalization | 107.3 M | ||||
| Total Asset | 226.62 M | ||||
| Retained Earnings | (52.31 M) | ||||
| Working Capital | 195.62 M | ||||
| Current Asset | 93.04 M | ||||
| Current Liabilities | 6.29 M | ||||
About XBiotech Performance
Assessing XBiotech's fundamental ratios provides investors with valuable insights into XBiotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the XBiotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (645.71) | (677.99) | |
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.21) | (0.22) |
Things to note about XBiotech performance evaluation
Checking the ongoing alerts about XBiotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for XBiotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| XBiotech generated a negative expected return over the last 90 days | |
| XBiotech has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 300 K. Net Loss for the year was (24.56 M) with profit before overhead, payroll, taxes, and interest of 3.36 M. | |
| XBiotech currently holds about 225.79 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.42, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| XBiotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company outstanding shares are owned by insiders |
- Analyzing XBiotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether XBiotech's stock is overvalued or undervalued compared to its peers.
- Examining XBiotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating XBiotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of XBiotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of XBiotech's stock. These opinions can provide insight into XBiotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.